Although point mutations of the 5′ noncoding regions of the BCL-6 proto-oncogene are frequently detected in B-diffuse large cell lymphoma (B-DLCL), a thorough analysis of the clinical correlation of these mutations has not been performed to date. In this study, BCL-6 mutations were examined by DNA direct sequencing in 103 patients with B-DLCL. BCL-6 mutations were found in 53/103 patients, including 38/76 treated with standard chemotherapy and 15/27 treated with autologous stem cell transplantation (ASCT) up front. The presence of BCL-6 mutations was correlated with clinical features at diagnosis and outcome. Mutated patients had a significantly higher LDH level (66% vs 38%, P Ͻ 0.05), and bulky disease (51% vs 32%, P = 0.05). In the whole series of patients BCL-6 mutations did not affect CR and OS. Patients with BCL-6 mutations tended to have a prolonged 5-years DFS and FFS compared to those without mutations (DFS 82% vs 63%, FFS 63% vs 49%). Among B-DLCL treated with standard chemotherapy, mutated patients showed a significantly improved 5-year DFS (85% vs 61%, P Ͻ 0.05) and, notably, the only four relapses observed among mutated patients occurred in less than 8 months. The multivariate regression analysis (P Ͻ 0.01) with DFS as endpoint confirmed the independent prognostic value of BCL-6 mutations. There was a trend for 5-year failurefree survival to be better for patients with BCL-6 mutations (63% vs 43%, P = 0.09). In the 27 patients treated with ASCT, BCL-6 mutations did not correlate with outcome. These results suggest that BCL-6 mutations may predict a higher chance of being free of disease in B-DLCL treated with standard chemotherapy. Larger series of patients need to be analyzed to evaluate the clinical relevance of BCL-6 mutations properly. Leukemia (2002) 16, 268-275.
Introduction
In recent years, molecular studies have revealed that the pathogenesis of B-DLCL is a heterogeneous process involving multiple independent molecular pathways. One such pathway involves BCL-6, a proto-oncogene mapping to chromosomal band 3q27 and encoding a POZ/zinc finger transcriptional repressor, which is required for germinal center formation and function. 1, 2 Two major types of genetic alterations may affect the BCL-6 gene in B-DLCL. The first type of BCL-6 alteration, occurring in approximately 30% B-DLCL, is represented by chromosomal alterations that lead to substitution of the gene Correspondence: U Vitolo, UOA Ematologia, Azienda Ospedaliera S Giovanni Battista, Cso Bramante 88 10188 Torino, Italy; Fax: 39 promoter with heterologous sequences derived from the partner chromosome. [3] [4] [5] [6] [7] The second type of genetic alteration affecting the BCL-6 gene is represented by point mutations of the 5′ noncoding regions of the gene. 8 Mutations of the BCL-6 gene are somatic in nature, may be biallelic and occur independent of cytogenetic alterations of band 3q27. The sequences affected by these mutations lie in the proximity of the BCL-6 promoter and overlap with the major cluster of chromosomal breakpoints. [8] [9] [10] [11] Mutations of the BCL-6 gene are regarded as a marker of B cell transit through the germinal center (GC) because, in normal lymphoid tissues, they occur in approximately 30% to 50% of GC and memory B cells, whereas they are absent in pre-GC and virgin B cells. [8] [9] [10] [11] [12] A large survey of B cell neoplasm has documented that BCL-6 mutations occur in approximately half of B-DLCL, including systemic nodal B-DLCL, primary extra nodal B-DLCL, CD5 +
B-DLCL, CD30
+ B-DLCL and primary splenic B-DLCL, whereas they are exceptional in primary mediastinal B-DLCL with sclerosis. 13 In advanced stage B-DLCL, current standard treatment may allow long-term survival in only 40% of the patients. The prognosis of advanced B-DLCL has possibly further improved with the introduction of more intensive regimens. [14] [15] [16] Moreover well-defined clinical prognostic features, such as the International Prognostic Index (IPI), 17 may stratify patients in different risk groups, in order to tailor the therapy. However, despite advances in treatment and more defined clinical indicators, approximately half of the patients with B-DLCL fail the therapy and die of their disease.
The term B-DLCL is therefore likely to include more than one disease entity and patients with B-DLCL have highly variable clinical behavior, outcome and natural history. 18 Because the molecular pathogenesis of B-DLCL is heterogeneous, it has been proposed that the tumor genotype may affect the clinical behavior and the outcome of the disease. The identification of new prognostic markers may help to further stratify patients into different risk groups. In this respect, several studies have reported the clinical relevance of some genetic lesions of B-DLCL, including gross rearrangements of BCL-6 and BCL-2 or alterations of tumor suppressor genes involved in RB1 and p53 pathways. 3, 4, 7, [19] [20] [21] [22] [23] Because some BCL-6 gene mutations have been suggested to deregulate the BCL-6 expression, 24 the presence of BCL-6 mutations may identify B-DLCL patients with possibly different biological behavior and clinical outcome. To date, however, the clinical relevance of BCL-6 mutations in B-DLCL patients has not been analyzed thoroughly.
The aim of the present study was to perform a detailed analysis of the clinical presentation and outcome in a cohort of de novo B-DLCL patients.
General characteristics of the patients
This retrospective study included patients with previously untreated diffuse large cell lymphoma with B phenotype (B-DLCL), who had been diagnosed and treated at four Italian institutions from 1986 to 1997. Criteria for inclusion into the study were a revised histopatologic diagnosis of B-DLCL according to the Real classification, 18 available DNA, adequate and uniform staging procedures, no age limits, any stage of disease and only treatment with doxorubicin-containing regimens already reported in the literature. One hundred and three patients entered into this study. Of these, 64 patients have been studied previously for molecular characterization of BCL-6 mutations. 13 They were followed up until 31 August 1999 or until death. The median follow-up duration from initiation of treatment for censored patients was 63 months. None of the patients had a history of previous low-grade lymphoma nor did the pathological material examined show areas of low-grade histology mixed with the B-DLCL pattern. Discordant B-DLCL cases were excluded from this study. Therefore all 103 patients were classified as de novo B-DLCL. Diagnosis was based on histopathology, immunophenotypic analysis of cell surface markers, and immunogenotypic analysis of immunoglobulin (Ig) gene rearrangement. 25 The histopathologic definition of B-DLCL was according to the REAL classification. 18 Based on previous data that showed that BCL-6 point mutations are extremely rare in primary mediastinal B-DLCL, this subset of B-DLCL patients were excluded from this study. 13 Patients positive for human immunodeficiency virus were not included in the study.
Staging
Staging included routine blood chemistry tests; blood cell counts and differential; ECG; chest X-ray; computed tomography (CT) of chest, abdomen and pelvis; and bilateral bone marrow biopsy in all patients. Gastrointestinal series with endoscopy, lumbar puncture with CSF examination and brain CT scan were performed only when there was clinical concern of gastrointestinal tract or CNS involvement. Disease stage was assessed according to the Ann Arbor criteria. 26 The extent of extranodal involvement was documented radiographically or pathologically. Bulky disease was assessed as a mass Ͼ10 cm in one diameter or more than one-third of the chest diameter in the mediastinum. Bone marrow involvement, but not spleen or Waldeyer lymphatic tissue, was scored as an extranodal site. Patients were scored according to the International Prognostic Index (IPI). 17 
Treatment
All patients included in the study were treated with an anthracycline-containing regimen. However, chemotherapy programs were different depending on the stage of disease, time of diagnosis and prognostic factors. Eleven patients with localized stage of disease without adverse prognostic features were treated with brief chemotherapy, ACOPB (adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) 27 or three courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone), 28 followed by locoregional radiotherapy at a dose of 36 Gy. Fifty-five patients with advanced Leukemia stage or localized stage with adverse prognostic features were treated with CHOP regimens (41 patients) or a third generation chemotherapy scheme such as MACOPB (methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) (seven patients) 29 or VACOPB (etoposide, adriamycin, cyclophosphamide, vincristine, prednisone, bleomycin) (seven patients). 30 Ten elderly patients, over 65 years, received PVEBEC (prednisone, vinblastine, epirubicin, bleomycin, etoposide, cyclophosphamide), 31 or VMP (etoposide, prednimustine, mitoxantrone) chemotherapy. 32 Twenty-seven patients, with advanced stage disease and adverse prognostic features at diagnosis were treated with a reduced course of standard chemotherapy (MACOPB or CHOP) followed by an intensification chemotherapy with peripheral blood stem cell harvest and high-dose chemotherapy BEAM (carmustine, etoposide, Ara-C, melphalan) with autologous stem cell transplantation. 14 
Assessment of response
Response to treatment was evaluated 1 month after the end of the therapeutic program. Restaging tests included blood chemistries and CT scans of chest, abdomen and pelvis in all patients and repetition of bone marrow biopsy if abnormal at diagnosis. Response criteria were defined according to the recent International Working Group recommendations. 33 Complete remission (CR) was defined as the absence of any detectable clinical and radiographic disease with disappearance of all disease-related symptoms. Complete remission unconfirmed (CRu) was considered as persistent clinical or radiographic lymphnode mass that has regressed by more than 75% of the initial tumor volume and no signs or symptoms of active disease. If the radiological abnormalities were subsequently stable for at least 3 months, the patients were judged to have a CR. Patients with a 50% or greater reduction in tumor volume were considered to be in partial remission (PR). Failure was defined as anything less than a PR, progressive disease or treatment-related death.
Analysis of BCL-6 mutations and rearrangements
Genomic DNA was performed as previously reported. 34, 35 Mutational analysis of the BCL-6 gene was performed by DNA direct sequencing of a unique PCR product encompassing 739 nucleotides (positions +404 to +1142) of the BCL-6 5′ noncoding regions. 13, 36 The choice of this fragment was based on the fact that Ͼ95% of BCL-6 mutations detected in B-DLCL fall within this region. 13 The PCR amplimer was amplified by primers E1.21B (5′-CTCTTGCCAAATGCTTTG-3′) and E1.26 (5′-CACGATACTTCATCTCATC-3′) and directly sequenced with forward or reverse primers using a commercially available kit (ThermoSequenase, Amersham Life Sciences, Amersham, UK). [␣-33 P]-labeled terminator dideoxynucleotides (Amersham Life Science) were included in the sequencing mixture. For each DNA fragment analyzed, sequencing of both strands was performed on independent PCR reactions. All the oligonucleotides used in this study were synthesized by the solid phase triester method. 13 Pilot experiments performed in our laboratory have shown that our mutation analysis technique allows the detection of BCL-6 mutations occurring in у5% of the tumor cell population.
Gross rearrangements of the BCL-6 gene were investigated by Southern blot analysis using probes (Sac4.0 and Sac0.8) and restriction enzymes (BamHI and XbaI) that, in combination, explore the cluster of chromosomal breakpoints detected in NHL. 13 Only cases showing abnormally migrating bands with two restriction enzymes and/or two probes were scored as rearranged. 13 
Analysis of BCL-2 rearrangement
Molecular analysis of BCL-2 rearrangement was performed as previously reported. 6 
Statistical methods
All the patients started on treatment were considered assessable. Survival includes all patients, with event defined as death of the patient due to any cause. Overall survival (OS) duration was measured from the beginning of treatment to the date of death or last follow-up alive. Failure-free survival (FFS) includes all patients, and was calculated from the beginning of treatment to the date of relapse, progression or death from any cause. Disease-free survival (DFS) applies only to the patients who achieved a CR or CRu: the duration was calculated from the time of CR or CRu assessment to the date of relapse or last follow-up free of disease. All curves were plotted according to the method of Kaplan 
Results

Patient characteristics
The clinical characteristics of the 103 patients are listed in Table 1 . The median age was 55 years (range 16 to 86 years). There were 55 males and 48 females. All case displayed a monoclonal B cell population as determined by immunophenotypic and/or immunogenotypic analysis. BCL-6 point mutations were found in 53 patients (51%), whereas they were absent in 50 (49%) cases. Rearrangements of BCL-6 were studied in 81 patients: 23 (28%) showed a gross rearrangement of BCL-6 and 58 (72%) did not. Of the 81 patients studied for both BCL-6 rearrangement and BCL-6 mutations, 13 showed both mutations and rearrangement, 33 displayed only mutations, 10 only rearrangement and 25 did not show any of the genetic lesions examined. CR, OS, DFS and FFS rates were not different between patients with or without BCL-6 rearrangement.
BCL-2 gene rearrangements were evaluated in 88 patients: 12 (14%) showed a rearrangement and 76 (86%) did not. BCL-2 rearrangement was present in 3/46 patients with BCL-6 mutations compared to 9/42 without BCL-6 mutations (P = NS). 
Correlation of BCL-6 point mutations with clinical features at diagnosis
The relationship between clinical features at diagnosis and BCL-6 point mutations status was analyzed. The results of these correlations are shown in 
Analysis of BCL-6 mutations and outcome
In the whole series of patients, complete response (CR + CRu) was observed in 73 patients (71%) and with a median followup of 63 months the predicted OS, DFS and FFS rates at 5 years were: 62%, 74% and 56%, respectively. (Figure 1a ). Only seven (5 CR and 2 CRu) of 38 complete responders with BCL-6 mutations relapsed compared to 12 of 35 CRs without mutations. All relapses in mutated patients occurred early within 1 year off therapy, whereas patients without mutations relapsed continuously up to 6 years. The 5-year FFS rate was higher in patients with BCL-6 mutations (63% vs 49%), however the difference was not statistically significant ( Figure 1b) . Our series includes patients treated with two different treatment approaches: standard chemotherapy and high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) up front. Patients treated with HDC and ASCT up front had a more prolonged 5-year FFS rates than those treated with standard chemotherapy (67% vs 53% P Ͻ 0.05). Thus in order to evaluate the prognostic impact of the presence of BCL-6 mutations on the outcome properly and to avoid a therapeutic bias, these two groups of patients were analyzed separately.
Among seventy-six patients treated with standard chemotherapy, 38 (50%) harbored BCL-6 point mutations. Clinical characteristics according to the presence or the absence of BCL-6 mutations are shown in Table 3 . As also observed for the whole series of patients, those with BCL-6 mutations had a significantly higher LDH level: LDH above normal in 22 mutated patients (63%) vs 10 unmutated ones (29%), P Ͻ 0.01. A higher incidence of bulky disease was also observed in mutated patients, however the difference was not statistically significant (P = 0.09).
The correlation between BCL-6 mutations and the outcome was evaluated in this group of 76 patients treated with standard chemotherapy. CR rate was superimposable between patients with or without BCL-6 mutations: 30/38 (71%) vs 25/38 (66%) patients. OS rate was slightly higher in those with BCL-6 mutations, although the difference was not statistically
Figure 1
Disease-free survival (DFS) and failure-free survival (FFS) according to BCL-6 mutations status in the whole series of 103 patients with B-DLCL. DFS (a) at 5 years was 82% for BCL-6-mutated patients (solid line) vs 63% for BCL-6-unmutated patients (dashed line) P = 0.08. FFS (b) at 5 years was 63% for BCL-6-mutated patients (solid line) vs 49% for BCL-6-unmutated patients (dashed line) P = NS. significant (5-year OS: 65% vs 56%). Conversely, patients with BCL-6 mutations showed a significantly higher 5-year DFS rate compared to those without this genetic lesion: 85% vs 61% (P Ͻ 0.05) (Figure 2a ). In particular, among B-DLCL who achieved CR, relapse occurred in 4/27 cases with BCL-6 mutations compared to 10/25 cases without BCL-6 mutations. The four relapses in patients with BCL-6 mutation occurred early in less than 8 months, compared with the continuous pattern of relapse, up to 69 months, observed in those without mutations. There was a trend for patients with BCL-6 mutations to have a better FFS (5-year FFS 63% vs 43% P = 0.09) (Figure 2b ). Of the 38 mutated patients, 14 failed and the last failure was observed at 20 months, whereas of the 38 unmutated patients, 21 failed with events observed continuously up to 88 months. At a significant level of P Ͻ 0.05, the multivariate regression analysis with DFS as an end point identified three prognostic factors for B-DLCL treated with standard chemotherapy: performance status, BCL-6 mutations and number of extranodal sites. This analysis confirmed the independent prognostic value of the presence of BCL-6 mutations for predicting a prolonged DFS (Table 4) .
In the 27 patients treated with HDC and ASCT, BCL-6 mutations were found in 15 patients (56%). In this group of patients there were no correlations between clinical features at diagnosis and BCL-6 mutations status. However, the majority of them had bulky disease (16 patients) or elevated LDH level (20 patients) at diagnosis. The presence of BCL-6 mutations did not correlate with different CR, OS, DFS or FFS rates.
Discussion
This study aimed at defining the clinical relevance of point mutations of the 5′ noncoding regions of the BCL-6 proto- Our series included two groups of patients, treated with two different therapeutic approaches, both of them containing anthracyclines: standard chemotherapy and high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) up front. With respect to outcome, the prognostic relevance of BCL-6 mutations was assessed both in the whole series of patients and in separate subsets of patients treated with either standard chemotherapy or with ASCT. This strategy seemed appropriate, since several studies have reported that ASCT may be superior to standard chemotherapy in achieving a cure for B-DLCL [14] [15] [16] 39, 40 and since patients treated with HDC and ASCT included in this study had a more favorable outcome than those treated with standard chemotherapy. Although our separate analysis according to therapy may help to avoid a potential bias in the assessment of the prognostic relevance of BCL-6 mutations, it does not allow any comparison between the two treatment groups of patients. In fact, treatment was not randomized and patients treated with HDC and ASCT were selected as younger, with a better performance status.
In the whole population of patients, the presence of BCL-6 mutations did not show statistically significant correlation with outcome. Conversely, in the group of 76 patients treated with standard chemotherapy, BCL-6 mutations appear to predict prolonged DFS despite their association with some poor clinical features at diagnosis, such as a higher LDH level or a higher incidence of bulky disease. Patients with BCL-6 mutations treated with standard chemotherapy had a markedly lower incidence of relapses: 85% of them were still alive and free of disease at 5 years compared with only 61% of unmutated patients. Also, the timing of relapse appears to be different in B-DLCL with or without BCL-6 mutations. The few relapses observed in the mutated group occurred early in less than 8 months, compared to the continuous pattern of relapses reported in the unmutated cases. There was a trend for patients with BCL-6 mutations to have a better FFS (5-year FFS 63% vs 43%). Although the difference between FFS curves was not statistically significant, mutated patients showed a clear plateau compared to unmutated patients who continued to fail up to 88 months. Unmutated patients do not represent cases carrying t(14;18), because BCL-2 rearrangement was found in a small proportion of patients regardless of the presence of BCL-6 mutations.
In our study, the prognostic value of BCL-6 mutations was found to be independent of other well-known prognostic factors of relapse, including performance status and number of involved extranodal sites as assessed by multivariate regression analysis with DFS as endpoint. Thus, patients with BCL-6 mutations, treated with standard chemotherapy, appear to have a good chance of cure once CR has been achieved.
The different DFS rate of patients with or without BCL-6 mutations was not influenced by the standard chemotherapy regimen used (data not shown). This is not surprising, considering that B-DLCL outcome is similar regardless of the second or third generation chemotherapy regimens adopted, as reported by large randomized trials. 41 The lack of statistically significant differences in overall survival rates between mutated and unmutated patients may be due to the impact of Leukemia salvage therapy, mainly HDC and ASCT, used in the patients who failed or relapsed after first-line treatment.
The apparent lack of prognostic evidence of BCL-6 mutations in the subset of patients treated at the onset with HDC and ASCT may be due to the small sample size and prompts future studies, on a large panel of patients, aimed at defining the clinical relevance of BCL6-mutations in this subset of patients.
The reasons for the apparent clinical differences between B-DLCL with and those without BCL-6 mutations are currently speculative. Although a pathogenetic role for BCL-6 mutations has not been formally established, indirect observations suggest that mutations may carry functional consequences. 24 In particular, it is remarkable that BCL-6 mutations cluster in highly conserved genomic regions, suggesting that some mutations may affect regulatory domains of BCL-6 and thus deregulate the physiologic expression of the gene. 24 In this respect, the presence of BCL-6 mutations, and consequently altered regulation of BCL-6 protein, may render the tumor clone more sensitive to full eradication by chemotherapy or, alternatively, less prone to relapse.
Recently, investigations exploiting DNA microarray technology has subdivided B-DLCL into two molecularly distinct subgroup with different gene expression profiles: germinal center (GC) B cell-like B-DLCL and activated B cell-like B-DLCL. 42 ,43 GC B cell-like B-DLCL displays many known markers of GC differentiation, such as elevated BCL-6 m-RNA levels and, interestingly, these patients did significantly better than those with activated B cell-like B-DLCL. Whether BCL-6 mutations may lead to higher BCL-6 mRNA levels, and thus to better prognosis, remains to be defined.
Although well-known clinical indicators, as those outlined by the IPI, may define the prognosis of B-DLCL, these patients continue to have different clinical features and outcome. Thus, it is commonly agreed that patients will certainly benefit from tailoring therapy to more precise subgroups of tumors. In particular, patients at high risk of relapse need an aggressive treatment early in the course of their disease, while those in good prognosis subgroups may be spared further therapy once CR has been achieved. On this basis, the results presented in this study may suggest a prognostic value of BCL-6 mutations, at least in patients treated with standard chemotherapy. This finding requires confirmation by investigations aimed at defining the potential prognostic value of BCL-6 mutations in larger series of patients.
